PremiumThe FlyArcutis Biotherapeutics presents new long-term results of ZORYVE cream Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam PremiumCompany AnnouncementsArcutis Biotherapeutics Reports Strong Q1 Earnings Growth Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements Arcutis Biotherapeutics: Strong Growth Prospects and Financial Stability Justify Buy Rating PremiumPre-EarningsARQT Earnings this Week: How Will it Perform? Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential Positive Outlook for Arcutis Biotherapeutics: Buy Rating Affirmed by Vikram Purohit